Hyperfine, Inc. — Director's Dealing 2021

Dec 24, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Hyperfine, Inc. (HYPR)
CIK: 0001833769
Period of Report: 2021-12-22

Reporting Person: Hughes Mark A. (Chief Operating Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-22	Class A Common Stock	A	19615	—	Acquired	19615	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-22	Stock Option (right to buy)	$3.76	A	21322	Acquired	2029-07-01	Class A Common Stock (21322)	Direct
2021-12-22	Stock Option (right to buy)	$3.76	A	54037	Acquired	2030-01-18	Class A Common Stock (54037)	Direct
2021-12-22	Stock Option (right to buy)	$3.76	A	3275	Acquired	2030-01-18	Class A Common Stock (3275)	Direct
2021-12-22	Stock Option (right to buy)	$3.27	A	4912	Acquired	2031-04-14	Class A Common Stock (4912)	Direct
2021-12-22	Stock Option (right to buy)	$3.27	A	60587	Acquired	2031-04-14	Class A Common Stock (60587)	Direct

Footnotes

F1: In connection with the closing of the transactions contemplated by the Business Combination Agreement, dated as of July 7, 2021, by and among HealthCor Catalio Acquisition Corp. ("HealthCor"), Optimus Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of HealthCor ("Merger Sub I"), Optimus Merger Sub II, Inc., a Delaware corporation and wholly owned subsidiary of HealthCor ("Merger Sub II"), Hyperfine, Inc.,

F2: a Delaware corporation ("Hyperfine"), and Liminal Sciences, Inc., a Delaware corporation ("Liminal"), pursuant to which Merger Sub I merged with and into Hyperfine (the "Hyperfine Merger"), with Hyperfine surviving the Hyperfine Merger as a wholly owned subsidiary of HealthCor, and Merger Sub II merged with and into Liminal (the "Liminal Merger" and, together with the Hyperfine Merger, the "Mergers"), with Liminal surviving the Liminal Merger as a wholly owned subsidiary of HealthCor (which changed its name to "Hyperfine, Inc.", the "Issuer"), these shares were received in exchange for 59,894 shares of Hyperfine common stock.

F3: The shares underlying this option vest as to 25% on September 30, 2020, with the remainder vesting in equal monthly installments, over the following three years, subject to Mr. Hughes's continued service through the applicable vesting date.

F4: Received in connection with the Mergers in exchange for a stock option to acquire 65,106 shares of Hyperfine common stock for $1.23 per share.

F5: The shares underlying this option vest as to 25% on December 31, 2020, with the remainder vesting in equal monthly installments, over the following three years, subject to Mr. Hughes's continued service through the applicable vesting date.

F6: Received in connection with the Mergers in exchange for a stock option to acquire 165,000 shares of Hyperfine common stock for $1.23 per share.

F7: The shares underlying this option vest as to 25% on December 31, 2020, with the remainder vesting in equal monthly installments, over the following three years, subject to Mr. Hughes's continued service through the applicable vesting date.

F8: Received in connection with the Mergers in exchange for a stock option to acquire 10,000 shares of Hyperfine common stock for $1.23 per share.

F9: The shares underlying this option vest in 48 equal monthly installments beginning on October 31, 2020, subject to Mr. Hughes's continued service through the applicable vesting date.

F10: Received in connection with the Mergers in exchange for a stock option to acquire 15,000 shares of Hyperfine common stock for $1.07 per share.

F11: The shares underlying this option vest in 48 equal monthly installments beginning on October 31, 2020, subject to Mr. Hughes's continued service through the applicable vesting date.

F12: Received in connection with the Mergers in exchange for a stock option to acquire 185,000 shares of Hyperfine common stock for $1.07 per share.